drugset / Trial / NCT00742508

A Phase I/II Clinical Study of SK&F-105517-D in Japanese Patients With Chronic Heart Failure

NCT00742508

Phase 1 Completed 41 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the safety and tolerability of SK\&F-105517-D in japanese patients with chronic heart failure.

Timeline

Start
2008-08-28
Primary completion
2009-08-21
Completion
2009-08-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Carvedilol Other / unclassified 2.5 mg
Subject Carvedilol Other / unclassified 10 mg
Subject SK&F-105517-D Unknown 10 mg
Subject SK&F-105517-D Unknown 20 mg
Subject SK&F-105517-D Unknown 40 mg